Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05007301 · ClinicalTrials.gov registry record
Geko™ Cross Therapy Registry - Wound
A clinical trial of Diabetic Foot Ulcer and Venous Leg Ulcer, sponsored by Firstkind.
- Active
- Registry status
- 2,500
- Enrollment target
- 3
- Study locations
NCT05007301: Active study of Diabetic Foot Ulcer and Venous Leg Ulcer, sponsored by Firstkind.
NCT05007301 is a study of Diabetic Foot Ulcer and Venous Leg Ulcer that is active but no longer recruiting, run by Firstkind. The registered enrollment target is 2,500 participants, above the 218-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (1047% higher). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05007301, a study of Diabetic Foot Ulcer and Venous Leg Ulcer, is active but no longer recruiting, sponsored by Firstkind.
- ACTIVE NOT RECRUITING
- Registry status
- 2,500 participants
- Enrollment target
- 3
- Study locations
Study Summary
The geko™ Cross Therapy REGISTRY - Wound is a prospective, observational, anonymised data collection Registry with no experimental treatment that will fulfil an unmet need for an observational Registry to provide long-term clinical data to demonstrate patient benefit and regulatory compliance.
Primary Outcome
Obtain frequency of adverse events (AEs) whether device related or not and compare rate to historic and published data i.e., geko™ therapy vs standard care without geko™ therapy
Conditions Studied
Interventions
- DEVICE geko device
Study Locations (3)
Other
- Central London Community Health Care NHS Trust - London
- Norfolk Community Health and Care NHS Trust - Norwich
New York
- Northwell Health System - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2022-04-04 |
| Est. Completion | 2028-03 |
What the registry record for NCT05007301 still lists
NCT05007301 is an observational study that tracks outcomes without assigning an intervention. Its 2,500 participants enrollment target places it among the larger protocols in the corpus, above the 218-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (1047% higher).
The record links to 4 conditions, with Diabetic Foot Ulcer appearing as the primary indexed condition, and to 1 intervention - of which geko device is the first listed.
NCT05007301 reports a single indexed study location in Other, New York.
Frequently Asked Questions
What is clinical trial NCT05007301 about?
NCT05007301 is a clinical study titled "Geko™ Cross Therapy Registry - Wound". The geko™ Cross Therapy REGISTRY - Wound is a prospective, observational, anonymised data collection Registry with no experimental treatment that will fulfil an unmet need for an observational Registry to provide long-term clinical data to demonstrate patient benefit and regulatory compliance.
What is the current status of trial NCT05007301?
This trial is currently active not recruiting. The enrollment target is 2,500 participants. The study started on 2022-04-04. Estimated completion is 2028-03.
What conditions does trial NCT05007301 study?
This clinical trial studies the following conditions: Diabetic Foot Ulcer, Venous Leg Ulcer, Wound, Arterial Leg Ulcer.
What interventions are being tested in trial NCT05007301?
The interventions under investigation include: geko device (DEVICE).
Who is sponsoring clinical trial NCT05007301?
This trial is sponsored by Firstkind, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05007301 being conducted?
This trial has 3 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Foot Ulcer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05007301's enrollment target sits among peer trials
2,500 2nd of 67 the highest of 67 other Diabetic Foot Ulcer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Foot Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Randomized Evaluation of Nonhealing Diabetic Foot Ulcers With Exclusive Wound Therapy
RECRUITING · Phase 4
-
Evaluating the Durability of Closure for Diabetic Foot Ulcers Following a Randomized, Controlled, Modified Platform Trial.
RECRUITING
-
Feasibility and Effectiveness of a Remote Monitoring Program for the Treatment of Diabetic Foot Ulcers
RECRUITING · NA
-
Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating DFU and SanoGraft® in Treating VLU to SOC
RECRUITING · NA
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
DFC 004 Biomarkers for Active Diabetic Foot Ulcers
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
- NCT02257229 · 2,500 participants
Prospective Evaluation of Treatment for Clubfoot
- NCT02530658 · 2,500 participants
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI